


16569 U.S.PTO
03240410/807320
032404**Patent Application Transmittal**

(only for new nonprovisional applications under 37 C.F.R. 1.53(b))

FIRM: ANDERSON KILL & OLICK, P.C. ADDRESS: 1251 Avenue of the Americas New York, New York 10020 TEL: (212) 278-1000 FAX: (212) 278-1733	EXPRESS MAIL Mailing label number: EV 331913981 US Date of Deposit: March 24, 2004 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: M/S Patent Application, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.
	<u>Naomi Mbys-Davidson</u> (Typed or printed name of person mailing paper or fee)  (Signature of person mailing paper or fee)
	[37 CFR § 1.8 Certificate of Mailing CANNOT be used.]

Date: March 23, 2004
Attorney Docket No.: DE-1503CIP

Mail Stop: PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

With reference to the filing in the United States Patent and Trademark Office of an application for patent in the name(s) of:

Young-Min KIM, Dae-Jin KIM, Sung-Min BAE, Chang-Ki LIM, Se-Chang KWON, and Gwan-Sun LEEEntitled: **PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE HAVING
PROLONGED IN VIVO HALF-LIFE** New Application Continuing Application Continuation Divisional Continuation-in-Part (CIP)
of 10/659,195, filed September 9, 2003.

[Note: If priority under 35 U.S.C. 120 involves a series of respectively co-pending applications, then in this amendment identify each and its relationship to its immediate predecessor.]

 The prior application is assigned of record to Hanmi Pharm. Co., Ltd. This is an application of a small entity under 37 CFR 1.9(f) and the amounts shown in parentheses below have been employed in calculating the fee:

The following are enclosed:

Specification including Abstract (59 pages)
 16 Sheet(s) of Drawings (Figs 1-16)
 53 Claim(s) (including 3 independent claims)
This application contains a multiple dependent claim
Information Disclosure Statement, PTO-1449 and ___ references;

____ This filing fee has been calculated on the basis of the claims as amended by any enclosed preliminary amendment as follows:

Basic Fee \$770.00 (\$385.00	\$770.00
Number of Claims in excess of 20 at \$18.00 (\$ 9.00) each:33	594.00
Number of Independent Claims in excess of 3 at \$84.00 (\$42.00) each	00.00
Multiple Dependent Claim Fee at \$290.00 (\$145.00).....	00.00
<input checked="" type="checkbox"/> Assignment Recording Fee \$40.00.....	40.00
Total Filing Fee.....	<u>\$1,404.00</u>

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication and credit any overpayment to Deposit Account No. 01-1944. A duplicate copy of this sheet is enclosed

(X) Any additional filing fees required under 37 CRF 1.16
(X) Any patent application processing fees under 37 CRF 1.17.

Oath or Declaration and Power of Attorney
 New signed unsigned
 Copy from a prior application (37 C.F.R. 1.63(d))

Deletion of Inventors

____ Signed Statement attached deleting inventor(s) named in the prior application (37 C.F.R. 1.63(d)(2) and 1.33(b))
____ Power of attorney and/or correspondence address was changed during prosecution of the prior application. The new power of attorney is to ___. The new correspondence address is indicated above.

____ Incorporation by Reference (for continuation or divisional application)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

____ A Preliminary Amendment is enclosed.
(Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

____ Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

New formal drawings are enclosed.

A receipt in the Case of an Original Deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Pursuit of Patent Procedure is enclosed.

 A Sequence Listing in computer readable format on diskette as well as a paper version and a statement according to the rules for submitting sequence listings are enclosed.


X Certified copy of each foreign priority application on which the claim for priority under 35 U.S.C. 119 is based is enclosed herewith. A list of said foreign priority application(s) is (are) provided below. Acknowledgement thereof is requested.

<u>Application No.</u>	<u>Filed</u>	<u>In</u>
10-2003-0036408	June 5, 2003	Republic of Korea
10-2003-0015744	March 13, 2003	Republic of Korea

X The Commissioner is hereby authorized to charge payment of the following fees during the pendency of the application or credit any overpayment to Deposit Account No. 01-1944. A duplicate copy of this sheet is enclosed

(X) Any patent application processing fees under 37 CFR 1.17
(X) Any filing fees required under 37 CFR 1.16 for the presentation of extra claims.

Respectfully submitted,
Attorneys for Applicant(s)

By: 
Richard B. Klar
Registration No. 31,385

Dated: March 23, 2004